Thalidomide (Thalomid, Celgene) as a treatment for multiple myeloma
Approvable designations
Fast-track designations
Orphan drug designations
Recommendations against approval
Medicare’s Drug Price Negotiations Could Impact Physician Reimbursement
September 19th 2024When CMS begins negotiations for physician-administered drugs under the Inflation Reduction Act, providers, including those whose services are covered by commercial insurance, could see lowered reimbursement.
Read More